 |
Top 6 Antibody-Drug Conjugate (ADC) startups
Updated: February 28, 2024 |
Antibody-drug conjugates (ADCs) are a class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, delivering the drug directly to cancer cells while minimizing damage to healthy tissues. By attaching a potent drug to an antibody that selectively binds to cancer cells, ADCs offer a promising approach for enhancing treatment efficacy and reducing systemic side effects in cancer patients.
1
Country: Switzerland | Funding: $751.6M
ADC Therapeutics is focused on the development of proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and hematological cancers. ADC Therapeutics employs monoclonal antibodies specific to particular tumor antigens conjugated to a novel class of highly potent pyrrolobenzodiazepine (PBD) -based warheads to selectively kill cancer cells.
ADC Therapeutics is focused on the development of proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and hematological cancers. ADC Therapeutics employs monoclonal antibodies specific to particular tumor antigens conjugated to a novel class of highly potent pyrrolobenzodiazepine (PBD) -based warheads to selectively kill cancer cells.
2
Country: USA | Funding: $247M
ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.
ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.
3
Country: Denmark | Funding: $97.3M
ADCendo is dedicated to developing antibody-drug conjugates (ADCs) for treatment of cancer. We are taking the ADC approach to new levels through a focus on cancer-associated targets that are professional internalizers and allow for superior selectivity via highly preferential cancer expression.
ADCendo is dedicated to developing antibody-drug conjugates (ADCs) for treatment of cancer. We are taking the ADC approach to new levels through a focus on cancer-associated targets that are professional internalizers and allow for superior selectivity via highly preferential cancer expression.
4
Country: Germany | Funding: €72M
Tubulis Technologies generates uniquely matched protein-drug conjugates ADCs that deliver drugs to tumors but still cause adverse events by shedding their payloads en route to the cancer.
Tubulis Technologies generates uniquely matched protein-drug conjugates ADCs that deliver drugs to tumors but still cause adverse events by shedding their payloads en route to the cancer.
5
Country: UK | Funding: $68M
Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers.
Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers.
6
Country: Switzerland | Funding: $65.7M
NBE-Therapeutics develops next-generation ADCs improving treatment options for cancer patients. The company is financially backed by the Boehringer Ingelheim Venture Fund and additional private investors.
NBE-Therapeutics develops next-generation ADCs improving treatment options for cancer patients. The company is financially backed by the Boehringer Ingelheim Venture Fund and additional private investors.